EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis

Stanislas Demuth iD, Igor Faddeenkov iD, Julien Paris iD, Olivia Rousseau iD, Béatrice Baciotti iD, Marianne Payet iD, Romain Casey iD, Sandra Vukusic iD, Senan Doyle iD, Guillaume Jarre, Nicolas Vince iD, Sophie Limou iD und 6 weitere

JAMIA Open · 05.05.2026 · 9 (3)

DOI: 10.1093/jamiaopen/ooag039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMIA Open, online erschienen am 09.05.2026. Verfasst von Stanislas Demuth und 17 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, Nantes University Hopital, Ecole Centrale Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The “Projections In Multiple Sclerosis” (PRIMUS) project aims to develop a precision medicine platform enabling neurologists to support therapeutic decisions in multiple sclerosis by visualizing similar patient data in a reference database. We present a data integration method to combine randomized clinical trials (RCTs) and observational studies data and optimize the informativeness of the resulting database. Material and Methods We developed an extract-transform-load data integration pipeline to combine 13 source databases: the “mother” and “high-definition” cohorts from the French MS registry and 11 industrial RCTs (31 786 patients). We aimed to inform each treatment class initiation with at least 500 patients with a 2-year clinical and MRI follow-up. Our data integration strategy used every patient visit as a potential baseline time point to inform a specific neurologist’ query to the platform, thus tailoring the actual analysis cohort to each visiting patient.

Results

The PRIMUS database had 12 953 patients with at least one informative visit, using the per-visit integration. It could inform treatment initiation scenarios with at least 485 patients for glatiramer acetate and at most 1754 for natalizumab. For instance, our per-visit integration method identified 1306 patients in the high-definition cohort against 610 with the classical epidemiological per-patient integration. Although the mother cohort’s longitudinal data were deemed sparse, we identified 6128 informative patients.

Discussion

Neurologists would query the PRIMUS database through a web application to support discussions with their patients and the selection of disease-modifying treatments.

Conclusion

Our data integration pipeline enabled the creation of a highly informative reference database.

Schlagwörter

Stichwörter der Autor:innen

ETLbig data & analyticsdata integrationmultiple sclerosisobservational studyprecision medicinerandomized clinical trial

Autor:innen und Institutionen

  • Nantes Université, Nantes University Hopital, Ecole Centrale Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, F-44000, France.
  • Inserm CIC1434 Clinical Investigation Center, University of Strasbourg, Strasbourg, 67000, France.
  • Biogen France S.A.S, Paris, 75000, France.
  • Neurology, Merck Santé S.A.S., Lyon, 69008, France.
  • Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, Université de Lyon, Lyon, 69000, France.
  • Service de Neurologie, sclérose en plaques, pathologies de la myéline et Neuro-Inflammation, Hospices Civils de Lyon, Bron, 69677, France.

ORCID-Profile: Stanislas Demuth, Igor Faddeenkov, Julien Paris, Olivia Rousseau, Béatrice Baciotti, Marianne Payet, Romain Casey, Sandra Vukusic, Senan Doyle, Nicolas Vince, Sophie Limou, Jérôme De Sèze, Anne Kerbrat, David Laplaud, Gilles Edan

Förderung

  • French National Research Agency

Zitieren

APA

Demuth, S., Faddeenkov, I., Paris, J., Rousseau, O., Baciotti, B., Payet, M., Casey, R., Vukusic, S., Doyle, S., Jarre, G., Vince, N., Limou, S., De Sèze, J., Kerbrat, A., Laplaud, D., Edan, G., Gourraud, P. A., & PRIMUS Consortium (2026). PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis. JAMIA Open, 9(3). https://doi.org/10.1093/jamiaopen/ooag039

Vancouver

Demuth S, Faddeenkov I, Paris J, Rousseau O, Baciotti B, Payet M, et al. PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis. JAMIA Open. 2026;9(3). doi:10.1093/jamiaopen/ooag039

BibTeX
@article{Demuth2026,
  author = {Demuth, Stanislas and Faddeenkov, Igor and Paris, Julien and Rousseau, Olivia and Baciotti, Béatrice and Payet, Marianne and Casey, Romain and Vukusic, Sandra and Doyle, Senan and Jarre, Guillaume and Vince, Nicolas and Limou, Sophie and De Sèze, Jérôme and Kerbrat, Anne and Laplaud, David and Edan, Gilles and Gourraud, Pierre-Antoine and PRIMUS Consortium, PRIMUS Consortium},
  title = {PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis},
  journal = {JAMIA Open},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1093/jamiaopen/ooag039}
}
Kostenlos starten →